Effects of Dose and Route of Administration on Pharmacokinetics of (±)-3,4-Methylenedioxymethamphetamine in the Rat
Open Access
- 13 August 2009
- journal article
- research article
- Published by American Society for Pharmacology & Experimental Therapeutics (ASPET) in Drug Metabolism and Disposition
- Vol. 37 (11), 2163-2170
- https://doi.org/10.1124/dmd.109.028506
Abstract
Based on animal data, there is speculation that (±)-3,4-methylenedioxymethamphetamine (MDMA) is neurotoxic to humans. Extrapolation of MDMA findings from animals to humans requires assessment of pharmacokinetics in various species, and low-dose administration data from rats are lacking. In this study, we examine MDMA pharmacokinetics in rats given low (2 mg/kg) and high (10 mg/kg) doses of racemic MDMA via intraperitoneal, subcutaneous, and oral routes. Repeated blood specimens were collected from venous catheters, and plasma was assayed for MDMA and its metabolites, 4-hydroxy-3-methoxymethamphetamine (HMMA) and 3,4-methylenedioxyamphetamine (MDA), by gas chromatography-mass spectrometry. After 2 mg/kg, maximum MDMA concentrations (Cmax) were ∼200 ng/ml for intraperitoneal and subcutaneous routes, but less for the oral route. MDMA plasma half-lives were 2 h. After 10 mg/kg, MDMA areas under the curve (AUCs) were 21-fold (intraperitoneal), 10-fold (subcutaneous), and 36-fold (oral) greater than those at 2 mg/kg. In contrast, HMMA AUC values in high-dose groups were Cmax values similar to those in humans, perhaps explaining why both species discriminate 1.5 mg/kg MDMA in laboratory paradigms. Second, our data provide additional support for nonlinear kinetics of MDMA in rats, and, analogous to humans, this phenomenon appears to involve impaired drug metabolism. Finally, given key similarities between MDMA pharmacokinetics in rats and humans, data from rats may be clinically relevant when appropriate dosing conditions are used.Keywords
This publication has 40 references indexed in Scilit:
- Further Studies on the Role of Metabolites in (±)-3,4-Methylenedioxymethamphetamine-Induced Serotonergic NeurotoxicityDrug Metabolism and Disposition, 2009
- Direct Comparison of (±) 3,4-Methylenedioxymethamphetamine (“Ecstasy”) Disposition and Metabolism in Squirrel Monkeys and HumansTherapeutic Drug Monitoring, 2009
- A validated gas chromatographic–electron impact ionization mass spectrometric method for methamphetamine, methylenedioxymethamphetamine (MDMA), and metabolites in mouse plasma and brainJournal of Chromatography B, 2008
- Physiological and Subjective Responses to Controlled Oral 3,4-Methylenedioxymethamphetamine AdministrationJournal of Clinical Psychopharmacology, 2008
- Plasma Pharmacokinetics of 3,4-Methylenedioxymethamphetamine After Controlled Oral Administration to Young AdultsTherapeutic Drug Monitoring, 2008
- Tolerance to 3,4-methylenedioxymethamphetamine in rats exposed to single high-dose bingesNeuroscience, 2008
- Ambient Temperature Effects on 3,4-Methylenedioxymethamphetamine-Induced Thermodysregulation and Pharmacokinetics in Male MonkeysDrug Metabolism and Disposition, 2007
- Discriminative stimulus effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans trained to discriminate among d-amphetamine, meta-chlorophenylpiperazine and placeboDrug and Alcohol Dependence, 2006
- Comparative investigation of disposition of 3,4-(methylenedioxy)methamphetamine (MDMA) in the rat and the mouse by a capillary gas chromatography—mass spectrometry assay based on perfluorotributylamine-enhanced ammonia positive ion chemical ionizationJournal of Pharmaceutical and Biomedical Analysis, 1992
- Spectral and inhibitory interactions of (±)−3, 4-methylenedioxyamphetamine (MDA) and (±)−3, 4-methylenedioxymethampetamine (MDMA) with rat hepatic microsomesLife Sciences, 1986